Showing results (41-50 of 82) with videos related to
Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.Journal of Clinical Medicine|December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving AtezolizumabGuillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.The European Respiratory Journal|August 12, 2017
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practicePascale Tomasini, Solenn Brosseau, Julien Mazières, et al.Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.Targeted Oncology|March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS StudyJean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.European Journal of Cancer (Oxford, England : 1990)|September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trialElisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.Pageof 9